NCT Number: NCT02966704
Stable Isotope Method to Assess Dietary Protein Quality
The evaluation of protein quality has been identified as the top priority question by the Food and Agricultural Organization (FAO) of the United Nations. However, the current available methods do not precisely estimate protein quality, or need invasive procedures. The proposed 'dual tracer approach' is a non-invasive method to evaluate protein quality in humans.
The present project characterizes the use of 15N-intrinsically-labelled milk protein as a reference-protein for development a non-invasive method that can be used to assess protein quality in human subjects
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–35 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
Rationale: The evaluation of protein quality has been identified as the top priority question by the Food and Agricultural Organization (FAO) of the United Nations. However, the current available methods do not precisely estimate protein quality, or need invasive procedures. The proposed 'dual tracer approach' is a minimal invasive method to evaluate protein quality in humans.
Objective: The present project characterizes the use of 15N-intrinsically-labelled milk protein as a reference-protein for development a minimal invasive method that can be used to assess protein quality in human subjects. For this purpose, our primary objectives are to define the digestive and metabolic behaviour and distribution of the 15N-intrinsically-labelled milk protein compared to the internal standard 13C-spirulina.
Study design: Randomized cross-over trial with two experimental meals. Study population: Healthy male and female, age 18-35y Intervention (if applicable): On two separate test days, subjects will receive a semi liquid meal (pudding) divided in 9 portions, (meal 1: 27 En% Protein,10 En% fat, 62 En% carbohydrates; meal 2: 14 En% Protein,10 En% fat, 75 En% carbohydrates), with intrinsically labelled 15N protein powder. Furthermore, the meal will contain a trace amount of 13C-labelled algae protein as an internal standard. Meals will differ in the amount (e.g. 50g or 25g) of 15N-labelled milk protein.
Main study parameters/endpoints: The ratio of isotopic enrichment (15N/13C) of (total) amino acids of the test meal and the blood plasma as determined by (gas chromatography-) isotope ratio mass spectrometry ((GC)-IRMS).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: A meal challenge with intrinsically labelled protein and addition of stable isotope tracer is frequently used in postprandial studies. Stable isotopes are naturally occurring isotopes and are not harmful for subjects, as there is no decay. Furthermore, placing venous catheters and blood sampling can occasionally cause a local haematoma or bruise and some participants may report pain or discomfort. Subjects have to come to the research facility three times, a screening visit of 1 hour, and 2 experimental days of 7 hours. Subjects will be financially compensated for participation.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy
- Age: 20 - 35 y
- BMI: 18.5 - 25 kg/m2
- Stable dietary habits
- Veins suitable for cannulation (blood sampling)
Exclusion criteria
- Having a history of medical or surgical events that may significantly affect the study outcome
- Medical drug use accept incidental use of paracetamol
- (Chronic) disease which might influence the study outcomes e.g. diabetes mellitus or any other endocrine disorder, active cardiovascular disease, hepatic disease, renal disease, cancer
- Milk protein intolerance
- Alcohol consumption of >14 (women) or > 21 (men) units per week
- Drug abuse
- Moderate intense physical activity (exercise) for more than 5 hours/week
- Reported weight loss or weight gain of > 3 kg in the month prior to pre-study screening
- Reported slimming diet, or medically prescribed diet
- Having a habitual diet with a protein content of <10 En% > 30 En%
- Reported vegan or macrobiotic life-style
- Recent blood donation (<1 month prior to Day 01 of the study)
- Not willing to comply to the controlled dietary intervention guidelines
- Not willing or afraid to give up blood donation during the study
- Personnel of Wageningen University, department of Human Nutrition, their partner and their first and second degree relatives
- Current and within 1 month participation in other research from the Division of Human Nutrition
- Not having a general practitioner
Treatment and study plan
Primary outcomes
-
ratio of isotopic enrichment
Time frame: 6 hours
Sponsors and collaborators
Lead sponsor
Wageningen University
Other
Registry information
Official study title
A Dual Stable Isotope Method to Assess Dietary Protein Quality in Humans: Characterization of Intrinsically Labelled 15N Milk Protein as a Reference Protein
Important dates
- Study start
- 2016
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Nov 17, 2016
- Registry last updated
- Dec 14, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluation of Amino Acids Bioavailability in a Food Product Based on a Vegetable Protein Combination
NCT06774911
Bioavailability and AUC, Biological Availability
Reus, Spain
View Trial DetailsBioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions
NCT03886766
Amorphous Solid Dispersions, Biological Availability
Basel, Switzerland
View Trial DetailsA Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
NCT06137703
Biological Availability
Miami, Florida, United States
View Trial DetailsRelative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
NCT05525910
Biological Availability, COVID-19
New Haven, Connecticut, United States
View Trial Details